Chemomab Therapeutics Ltd DRC (CMMB NASDAQ) stock market data APIs
$2.6807
-0.06(-2.2%)
as of November 5, 2025
Try our APIs with
free plan!
Chemomab Therapeutics Ltd DRC Financial Data Overview
Price chart is built with
Anychart
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Prev. Close
2.6807
Open
2.6178
High
2.8224
Low
2.5928
52 wk Range
2.39-9.84
Market Cap
13 860 K
Shares Outstanding
5 191 K
EPS
0
Beta
0.545
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Chemomab Therapeutics Ltd DRC data using free add-ons & libraries
Get Chemomab Therapeutics Ltd DRC Fundamental Data
Chemomab Therapeutics Ltd DRC Fundamental data includes:
- Net Revenue:
- EBITDA: -12 613 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-07
- EPS/Forecast: -0.005
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chemomab Therapeutics Ltd DRC News
New
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data P...
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
Alkermes plc ALKS announced that it has entered into a definitive agreement to acquire Ireland-based Avadel Pharmaceuticals AVDL in a deal valued at up to $20.00 per share in cash, representing a tota...
Best Momentum Stocks to Buy for Oct. 23
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Oct. 23: Par Pacific Holdings, Inc. PARR: This energy and infrastructure business has a Zacks ...
New Strong Buy Stocks for Oct. 23: MQ, GES and More
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Marqeta, Inc. MQ: This card issuing platform has seen the Zacks Consensus Estimate for its current year earnings increasing 42...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
